Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Katja Rohwedder
ResearcherPublications, citations & collaboration network
Katja Rohwedder is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 132 works, 2,060 citations, an h-index of 16 and an i10-index of 28.
132
Works
2,060
Citations
16
h-index
28
i10-index
IDs:OpenAlex
How has Katja Rohwedder's publication output changed over time?
ScholarIQpublication output · 2011–2026
Output grew0% over the shown period — from 1 works in 2011 to 1 in 2026.
1
1
1
3
1
1
1
1
1
1
2011201320142015201820202023202420252026
What are the most-cited papers on Katja Rohwedder?
ScholarIQmost cited works
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin
Michael A. Nauck, Stefano Del Prato, Juris J. Meier, S. Durán‐García, Katja Rohwedder, M. Elze, Shamik Parikh
Diabetes Care. 2011534 CitationsOPEN ACCESS
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
John Wilding, Vincent Woo, Katja Rohwedder, Jennifer Sugg, Shamik Parikh, for the Dapagliflozin 006 Study Group
Diabetes Obesity and Metabolism. 2013296 CitationsOPEN ACCESS
Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data
Stefano Del Prato, Michael A. Nauck, S. Durán‐García, Laura Maffei, Katja Rohwedder, A. Theuerkauf, Shamik Parikh
Diabetes Obesity and Metabolism. 2015233 Citations
Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
S. Matthäei, Keith Bowering, Katja Rohwedder, A Grohl, Shamik Parikh, for the Study 05 Group
Diabetes Care. 2015150 Citations
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
Michael A. Nauck, Stefano Del Prato, S. Durán‐García, Katja Rohwedder, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh
Diabetes Obesity and Metabolism. 2014114 Citations
Related on ScholarIQ
Brigham and Women's Hospital
Institution
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin
Paper
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
Paper
Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data
Paper
Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
Paper
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
Paper